TheraRadar

Anthera

Pre-Approval PRO BETA

Inactive Company

No clinical trial activity in 3+ years. This company may have been acquired, shut down, or pivoted away from clinical development. Last trial started: 9/1/2016

17
Total Trials
9
Phase 3
7
Phase 2
0
Recruiting
197
Score

Pipeline by Phase

Phase 3
9
Phase 2
7
Phase 1
2

Therapeutic Focus

Systemic Lupus Erythematosus Exocrine Pancreatic Insufficiency Cystic Fibrosis IgA Nephropathy Acute Coronary Syndrome

Clinical Trials (17)

NCT02279498 Phase 3 COMPLETED

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Started: 6/1/2015

NCT02734810 Phase 3 COMPLETED

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Started: 6/1/2016

NCT02514967 Phase 3 TERMINATED

CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Started: 6/1/2016

NCT01395745 Phase 3 COMPLETED

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

Started: 2/1/2013

NCT02074020 Phase 3 WITHDRAWN

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Started: 12/1/2015

NCT02052219 Phase 3 WITHDRAWN

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Started: 10/1/2014

NCT01130246 Phase 3 TERMINATED

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

Started: 5/1/2010

NCT02062684 Phase 2 COMPLETED

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

Started: 6/1/2013

NCT01609452 Phase 2 WITHDRAWN

MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP

Started: 12/1/2015

NCT01598857 Phase 2 WITHDRAWN

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

Started: 12/1/2014

NCT01522196 Phase 2 TERMINATED

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

Started: 2/1/2012

NCT01162681 Phase 2 COMPLETED

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Started: 7/1/2010

NCT00743925 Phase 2 COMPLETED

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes

Started: 7/1/2008

NCT01305746 Phase 2 COMPLETED

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Started: 4/1/2011

NCT01359579 Phase 1 TERMINATED

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Started: 6/1/2011

NCT01359605 Phase 1 COMPLETED

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Started: 6/1/2011

NCT02823964 Phase 4 COMPLETED

EASY: Extended Access to Sollpura Over Years

Started: 9/1/2016

Drug Candidates

Liprotamase porcine (pig) PERT Liprotamase Powder for Oral Solution Blisibimod Placebo blisibimod Varespladib A-623 Varespladib Methyl (A-002) A-002, varespladib methyl
Activity Status: Inactive
Last Trial Started: 9/1/2016
Last Trial Ended: 3/1/2018
Trials (12 months): 0
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.